Cannabis Trademarks Not Stoned by PTO
Client Alert | 1 min read | 05.07.19
In new guidelines issued this past Thursday, May 2, 2019, the United States Patent & Trademark Office clarified the procedure for examining trademarks for cannabis-derived goods, services involving cannabis, and cannabis production. These guidelines explain that the 2018 Farm Bill exempts hemp (defined as cannabis plants and derivatives such as CBD that contain no more than 0.3 percent THC on a dry-weight basis) from the definition of marijuana in the Controlled Substances Act (21 U.S.C. § 801 et seq.)(CSA).
Thus, for applications that identify goods and/or related services encompassing cannabis or CBD, the 2018 Farm Bill potentially removes the CSA as a ground for refusal of registration under the following conditions:
- The goods and/or related services are derived from hemp.
- The identification of goods and/or services specify that the hemp products contain less than 0.3 percent THC.
- The application was filed on or after December 20, 2018, except that for applications filed before December 20, 2018, applicants have the option of amending the filing date and filing basis of the application to overcome the CSA as a ground of refusal.
Despite these guidelines, applicants should be aware that hemp related goods and/or services may still raise lawful-use issues under other laws, including the Federal Food Drug and Cosmetic Act (FDCA).
A link to the guidelines may be accessed here: USPTO Examination Guide 1-19.
Contacts
Insights
Client Alert | 2 min read | 09.18.25
On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”
Client Alert | 3 min read | 09.17.25
Client Alert | 4 min read | 09.17.25
Client Alert | 5 min read | 09.16.25
Bucking the Odds: Why Technology Companies Should Embrace Software Patents Today